#United States #Cambridge #Particles for Humanity #PFH-VAP #Marcus Chapman

Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of Finance

CAMBRIDGE, Mass. – January 13, 2026 – Particles for Humanity is excited to announce the appointment of Marcus Chapman as the Senior Vice President and Head of Finance. This strategic hiring comes at a crucial time as the organization gears up for the commercial launch of PFH-VAP, a stable formulation of vitamin A designed for large-scale food fortification, anticipated in 2026.

Chapman brings a wealth of experience to the table, accumulated over more than 20 years in operational, strategic, and financial roles across both emerging and established companies. His prior role was as Senior Vice President at Flagship Pioneering, where he was responsible for the financial strategy of a Pioneering Business Unit, and collaborated closely with a portfolio of early-stage companies, guiding them from inception through early funding rounds.

Prior to his tenure at Flagship Pioneering, Chapman held notable positions in the biopharmaceutical sector, including Principal Financial Officer at Seres Therapeutics and Head of Finance for Takeda Pharmaceuticals' Oncology Business Unit. His expertise is further underscored by a formative background in life sciences, having served as an Engagement Manager at Strategic Decisions Group and Clarion Healthcare. He holds an MBA from The Tuck School at Dartmouth College and a BA in Economics from Wheaton College.

Sherri Oberg, President and CEO of Particles for Humanity, expressed enthusiasm regarding Chapman's addition, stating, “We’re thrilled to welcome Marcus Chapman to Particles for Humanity. He combines operational rigor with strategic insight, and his leadership will be instrumental as we advance our mission.”

Chapman steps into this leadership role at a pivotal juncture for Particles for Humanity. The organization is poised to introduce PFH-VAP into the commercial market in Africa as part of a concerted effort to combat vitamin A deficiency, a pressing public health issue affecting millions worldwide. His deep-rooted financial and strategic acumen will play a critical role in navigating the transition from development to commercialization, ensuring the company achieves sustainable growth and meaningful impact.

Particles for Humanity is committed to transforming early-stage medical technology into viable products for individuals living in low and middle-income countries. Guided by a meticulous product development process that prioritizes end-user feedback, the organization focuses on creating financially sustainable product opportunities. Remarkably, all of its funding is sourced from philanthropic efforts. To learn more about Particles for Humanity, visit www.particlesfh.com or contact [email protected].